New Cancer Drug for Children With Hard-to-Treat Solid Tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called ifinatamab deruxtecan in children whose solid tumors (cancers that form lumps, excluding brain tumors) have come back or stopped responding to previous treatments. The drug is designed to target and kill cancer cells while potentially causing fewer side effects than standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child's cancer has come back or stopped responding to at least one prior treatment, and standard options are not available or didn't work
- Your child is between 1 month and 12 years old (Part 1) or 1 month and 18 years old (Part 2)
- Your child has recovered from previous cancer treatments to mild side effects or baseline, or has managed side effects with appropriate therapy
- Your child does not have active brain or spinal cord tumors (though stable, previously treated brain tumors may be okay)
- Your child does not have certain serious heart, lung, eye, or immune system conditions that could be made worse by the study drug
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, patritumab deruxtecan, in children and adolescents whose rhabdomyosarcoma or hepatoblastoma has returned or not responded to at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing.
This study tests a new drug called Ifinatamab Deruxtecan (I-DXd) for people with several types of advanced cancer that has grown despite standard treatments. The drug is designed to target and attack cancer cells directly, potentially shrinking tumors or slowing their growth.
This early-stage trial tests an investigational antibody-drug medicine (ifinatamab deruxtecan) in people with advanced solid tumors. It aims to see whether it can shrink tumors or help control cancer, and to learn about side effects and the best way to use it.
This study tests a new drug, ifinatamab deruxtecan, against the doctor's choice of standard treatments for people with extensive-stage small cell lung cancer that has returned after initial platinum-based chemotherapy. The goal is to see if the new drug works better and if it might be a new option for you.
This trial tests a new drug called Ifinatamab Deruxtecan for people with advanced esophageal squamous cell carcinoma that has progressed after one or two prior treatments. It aims to see if the drug can shrink tumors or slow the disease.
This trial tests a new drug, Ifinatamab Deruxtecan, for people with advanced esophageal squamous cell carcinoma that has worsened after standard treatments. It aims to see if it can help shrink or slow the cancer.
Hear when a new Malignant Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.